Bruce Feinberg, DO

Compared with first-line immunotherapy or chemotherapy alone, combination chemoimmunotherapy for advanced/metastatic non–small cell lung cancer has significantly higher antineoplastic drug and associated medical costs.

Recommendations to address limitations in more widespread use of reflex testing in community oncology.

How payers will support the use of comprehensive genomic profiling in oncology moving forward.

Expectations regarding the future utilization of comprehensive genomic profiling in clinical practice to assess patients with solid tumor cancers.

Payer perspective regarding decisions for covering the costs of molecular assays in oncology and reimbursing oncologists for treatments provided to patients while navigating long turnaround times associated with reflex testing.

Variables that impact decisions to initiate therapy for solid tumor cancers versus wait for results of genomic profiling assays.

Oncologists explain scenarios for which they may retest patients previously assessed via genomic profiling.

Criteria used by payers to determine how to code and support the use of various genomic profiling assays used in oncology.

Oncologists describe how they use molecular profiling in their practices to assess patients with solid tumor cancers.

Payer response to supporting decisions for coverage of comprehensive genomic profiling in oncology.

How to determine what information from comprehensive genomic profiling assays is relevant vs extraneous when making treatment decisions for patients with solid tumor cancers.

The rationale for migrating away from single, spot testing to comprehensive genomic profiling assays in oncology.

Panelists look toward the future management of myelodysplastic syndromes with respect to novel agents and treatment pathways.

Experts reflect on interchangeability between oral and intravenous therapy in patients with higher-risk myelodysplastic syndromes.

Oncologists who manage patients with solid tumors compare and contrast current comprehensive molecular assays being used in clinical practice and discuss reimbursement criteria with payer, Eugean Jiwanmall, MPH, MBA.

How the identification of certain driver mutations analyzed by genomic assays can be applied into oncology treatment.

Shared insight on the historical and current use of hypomethylating agents in patients with myelodysplastic syndromes.

Perspectives on the use of oral HMA therapy in higher-risk myelodysplastic syndromes, and how this has improved patient care.

Considerations regarding coverage decisions to support the large amount of information provided by molecular testing assays and the validity of results in terms of clinical decision-making.

Information that can be extracted from results of comprehensive genomic profiling assays and used to guide treatment decisions in oncology.

Expert panelists discuss when it’s appropriate to consider or continue ESA therapy or blood transfusions in patients with MDS.

Panelists share insight on therapeutic goals when treating patients with myelodysplastic syndromes.

Payer perspective regarding updates to coverage for comprehensive genomic profiling, becoming more widely used in oncology practice.

A brief review of disease and patient factors that influence the selection of therapy for myelodysplastic syndromes.

Reflections on the historical use of ESAs and blood transfusions to treat patients with myelodysplastic syndromes.

Experts consider shortcomings in the identification and management of myelodysplastic syndromes.

Practical perspectives on how to communicate MDS subclassifications with affected patients and caregivers.

Expert perspectives on the changes in MDS subclassifications as understandings of the disease have evolved.

Shared insight on how to best educate patients and caregivers on the broad nature of myelodysplastic syndromes.

A panel of experts discuss the complex nature of myelodysplastic syndromes and concurrent subclassifications.